Future studies to promote the translation of FAK+MEK inhibitor combination therapy into GBM clinical trials include broader profiling across a larger panel of diverse GBM stem cell models and correlation of phenotypic outcome with gene expression profiles using advanced statistical analysis methods and computational tools such as VISAGE [70] to identify potential patient stratification biomarkers that predict optimal synergy to support future personalized medicine strategies in GBM. This evidence concerns the gene PTK2 and glioblastoma.